Literature DB >> 20198227

New reduction pathways for ctc-[PtCl2(CH3CO2)2(NH3)(Am)] anticancer prodrugs.

Alina Nemirovski1, Inbal Vinograd, Khuloud Takrouri, Ana Mijovilovich, Annette Rompel, Dan Gibson.   

Abstract

Reduction of anticancer prodrugs such as ctc-[PtCl(2)(CH(3)CO(2))(2)(NH(3))(Am)] can yield three products in addition to the expected cis-[PtCl(2)(NH(3))(Am)]. A possible explanation is that reduction proceeds by several pathways where in addition to the loss of two axial ligands, one axial (acetato) and one equatorial (chlorido) ligand, or two equatorial ligands are eliminated.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20198227     DOI： 10.1039/b925721g

Source DB:  PubMed          Journal:  Chem Commun (Camb)        ISSN： 1359-7345            Impact factor:   6.222


  15 in total

1.  Oxidative halogenation of cisplatin and carboplatin: synthesis, spectroscopy, and crystal and molecular structures of Pt(IV) prodrugs.

Authors:  Timothy C Johnstone; Sarah M Alexander; Justin J Wilson; Stephen J Lippard
Journal:  Dalton Trans       Date:  2015-01-07       Impact factor: 4.390

2.  Antiproliferative Pt(IV) complexes: synthesis, biological activity, and quantitative structure-activity relationship modeling.

Authors:  Paola Gramatica; Ester Papa; Mara Luini; Elena Monti; Marzia B Gariboldi; Mauro Ravera; Elisabetta Gabano; Luca Gaviglio; Domenico Osella
Journal:  J Biol Inorg Chem       Date:  2010-06-06       Impact factor: 3.358

Review 3.  Redox activation of metal-based prodrugs as a strategy for drug delivery.

Authors:  Nora Graf; Stephen J Lippard
Journal:  Adv Drug Deliv Rev       Date:  2012-01-25       Impact factor: 15.470

Review 4.  Synthetic methods for the preparation of platinum anticancer complexes.

Authors:  Justin J Wilson; Stephen J Lippard
Journal:  Chem Rev       Date:  2013-11-27       Impact factor: 60.622

5.  Synthesis, characterization, and cytotoxicity of platinum(IV) carbamate complexes.

Authors:  Justin J Wilson; Stephen J Lippard
Journal:  Inorg Chem       Date:  2011-03-01       Impact factor: 5.165

6.  Using an RNAi Signature Assay To Guide the Design of Three-Drug-Conjugated Nanoparticles with Validated Mechanisms, In Vivo Efficacy, and Low Toxicity.

Authors:  Jonathan C Barnes; Peter M Bruno; Hung V-T Nguyen; Longyan Liao; Jenny Liu; Michael T Hemann; Jeremiah A Johnson
Journal:  J Am Chem Soc       Date:  2016-09-14       Impact factor: 15.419

7.  Photoinduced reduction of Pt(IV) within an anti-proliferative Pt(IV)-texaphyrin conjugate.

Authors:  Grégory Thiabaud; Jonathan F Arambula; Zahid H Siddik; Jonathan L Sessler
Journal:  Chemistry       Date:  2014-06-24       Impact factor: 5.236

8.  Monofunctional and higher-valent platinum anticancer agents.

Authors:  Timothy C Johnstone; Justin J Wilson; Stephen J Lippard
Journal:  Inorg Chem       Date:  2013-06-05       Impact factor: 5.165

Review 9.  Anticancer activity of metal complexes: involvement of redox processes.

Authors:  Ute Jungwirth; Christian R Kowol; Bernhard K Keppler; Christian G Hartinger; Walter Berger; Petra Heffeter
Journal:  Antioxid Redox Signal       Date:  2011-05-11       Impact factor: 8.401

10.  Theoretical investigations and density functional theory based quantitative structure-activity relationships model for novel cytotoxic platinum(IV) complexes.

Authors:  Hristo P Varbanov; Michael A Jakupec; Alexander Roller; Frank Jensen; Mathea Sophia Galanski; Bernhard K Keppler
Journal:  J Med Chem       Date:  2012-12-27       Impact factor: 7.446
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.